Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s president and CEO Rodney Varner will present at the Virtual Investor Conference Small and Microcap Showcase at 11 AM ET on February 4, 2021. Varner will be providing a virtual company overview, including a synopsis of its diabetes gene therapy and details on the recent progress made on GNPX’s upcoming clinical trials for the treatment of non-small cell lung cancer. Following the conference, a replay of GNPX’s presentation will be available on the company’s website for a limited time. A video will also be archived on www.VirtualInvestorConferences.com.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA(TM) (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced that it has entered into a definitive agreement to acquire Upright Technologies Ltd., a digital musculoskeletal (“MSK”) company; the acquisition will be in the form of a stock transaction. The acquisition is designed to expand DarioHealth’s multi-condition platform into the $213 billion musculoskeletal market and create one of the most comprehensive digital health platforms. The move also brings together complementary companies with industry-leading consumer engagement and clinical outcomes. In addition, DRIO has entered into definitive agreements with a group of health-care institutional investors to raise $70 million through a private placement. That financing includes several leading health-care focused institutional investors such as Nantahala Capital Management LLC, Perceptive Advisors, Driehaus Capital Management, Farallon Capital Management, Pura Vida Investments, and others. “I am very pleased to be able to achieve this milestone and expect that MSK will be a meaningful growth driver for our company for years to come,” said Dario CEO Erez Raphael in the press release. “We are committed to delivering the industry’s most comprehensive, clinically proven solution for the management of chronic conditions, and the addition of Upright, which is an expansion of our core competency, represents a significant step toward that goal. With similar approaches to building highly engaging and clinically effective products and similar cultures, I anticipate a rapid and seamless integration.”
DarioHealth is a leading global, digital-therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market; its highly engaging, user-centric MyDario(TM) mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Wednesday, January 27th, 2021UncategorizedComments Off on $DRIO Signs Agreements to Acquire Leading Digital Musculoskeletal Company, Raise $70 Million Through Private Placement
The novel coronavirus has affected many countries, infecting roughly 96.2 million people across the globe. Of the 96 million individuals, about 53 million have recovered from this disease while nearly 2 million individuals have, sadly, succumbed to the deadly infection.
Researchers have been trying to figure out how long the immunity of an individual who recovered from the disease will last. A recent study by Rockefeller University researchers provides an answer to this, suggesting that individuals who recover from the coronavirus are protected against the deadly infection for about six months, and likely much longer.
The study’s findings provide strong evidence showing that the immune system remembers the infection and continues to provide better antibodies even after the infection has subsided. The researchers discovered that the antibodies that are produced months after the infection had waned demonstrated an added ability to obstruct SARS-CoV-2 as well as the mutated versions of this infection. The researchers also discovered that continued exposure of immune cells to the virus remnants that were found in the gut tissue led to the production of improved antibodies.
Based on these discoveries, researchers surmise that when individuals who have recovered from the infection encounters the virus again, their immune response would not only be more effective but would also be more rapid, thus preventing re-infection.
Prof. Michel C. Nussenzweig, the head of Rockefeller’s laboratory of molecular immunology, whose team has been studying the response of antibodies in coronavirus patients, explained that the type of immune response that had been observed during the study could potentially be used to offer protection from the virus for a while, which would allow an individual’s body to prepare an effective and fast response to the virus upon re-exposure.
In order to understand how the antibodies worked in SARS-CoV-2, Nussenzweig and his team observed the responses of antibodies in 87 participants: the first time one month after the participants had been infected with the virus and a second time six months later.
They discovered that while the antibodies could still be detected at the second timepoint, their numbers had decreased significantly. Laboratory experiments conducted demonstrated that the ability of the plasma samples extracted from a patient to wipe out the virus had declined by about five times.
The researchers also looked into the SARS-CoV-2 virus replicating some of its cells in small intestine, upper throat and lung tissue. To help with this, the team collaborated with former Rockefeller scientist Saurabh Mehandru, who has been studying intestinal tissue biopsies from individuals who had recovered from the coronavirus.
They found that of the 14 patients who had tests conducted on them, seven of them had the genetic material and proteins of SARS-CoV-2 in the cells that line their intestines. The team of researchers is planning on studying more patients in a bid to better understand the role these viral remnants play both in an individual’s immunity and the disease’s progression.
Away from Sars-Cov-2, chronic noncommunicable diseases such as diabetes have been taking a toll on communities, and many companies are taking steps to address the treatment needs of the affected people. An example is DarioHealth Corp. (NASDAQ: DRIO), a company that has at least 51,000 active users of their smartphone-based digital solution that makes it easier for patients to make lasting lifestyle changes in order to lower the toll of their health conditions.
NOTE TO INVESTORS: The latest news and updates relating to DarioHealth Corp. (NASDAQ: DRIO) are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Wednesday, January 27th, 2021UncategorizedComments Off on $DRIO New Study Discovers Patient’s Immune System Continues Building Resistance After Recovering from COVID-19
Justin Andrews, co-founder of Halifax Psychedelic Society, a not-for-profit organization providing a safe space to connect and talk about psychedelics, is concerned that information on harm minimization strategies with regard to psychedelics is not being treated as a priority in Nova Scotia.
Andrews assisted in the establishment of the organization in 2018. The objective of the organization was to offer harm-reduction information and a support system to individuals who would be interested in using psychedelic substances such as LSD and psilocybin as a therapeutic treatment.
In this respect, harm-minimization strategies would comprise information about how to consume the psychedelic substances properly. This may also include how to prepare the said drug as well as dosage levels. In addition, it could also include insights on how to manage a “bad trip”, or a disagreeable experience that is usually set off by hallucinogenic drugs.
Andrews explained that while it wasn’t until 2016 that he began taking interest in psychotherapy using psychedelics, harm minimization had always been a priority.
Both the society and Andrews are supportive of the legal use of psychedelic substances in psychotherapy. Andrews explained that he had observed a surge in interest from individuals who sought out information about the use of psychedelics. This, he said, was the reason why it was important to have harm-reduction resources available to individuals in Nova Scotia.
Additionally, Andrews observed that there was an increasing trend in underground therapy. With people excited about the healing potential of psychedelics, it was important to emphasize the need for individuals to know and understand the policy and politics behind psychedelics.
At the moment, the Nova Scotia Health Authority does not provide any harm-minimization information on psychedelics except when it’s included in a treatment plan for addiction.
Society president Jeff Toth, who is also a psychiatric nurse, explained that recent studies have discovered the therapeutic benefits of various psychedelics such as MDMA, LSD and psilocybin and how they can be used to treat addiction, depression and even post-traumatic stress disorder. However, he added that more research was required as the evidence that had been gathered till now was regarded as preliminary evidence.
However, it seems a lot more will be required for NSHA to start providing harm-minimization literature. NSHA’s mental health and addictions department stated in an email that the Nova Scotia Health Authority had no plans to release harm-minimization literature on the therapeutic use of psychedelics as it had not encountered a high demand for that information thus far.
As research into psychedelics advances, many companies are positioning themselves to tap the growing market. For instance, Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is developing unique systems to deliver psychedelic medicines for a variety of therapeutic indications.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTC: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
Wednesday, January 27th, 2021UncategorizedComments Off on $CLXPF Advocates Worried by Insufficiency of Information on Psychedelic Treatments in Nova Scotia
Company will initiate a Phase II adult trial for Berubicin this year focused on patients with glioblastoma multiforme
WPD, a CNS sub-license partner, will be commencing a parallel Phase II adult trial and the first-ever pediatric Berubicin trial
Additional clinical trials are in the pipeline, including one for the company’s newest drug candidate, WP1244, and its effects on central nervous system tumors
Biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) recently took part in the H.C. Wainwright Bioconnect 2021 Virtual Conference, which took place January 11-14, 2021. CNS’s CEO John Climaco gave a presentation at the event, discussing how the clinical-stage biopharmaceutical company is developing novel treatments for primary and metastatic cancers of the brain and central nervous system (https://ibn.fm/7zYST).
CNS’s lead drug candidate is Berubicin, an anthracycline that, based on clinical data, can cross the blood-brain barrier in adults and reach the tumor cells of patients with brain cancer. As an organ targeted therapeutic, Berubicin demonstrated one durable complete response (not detectible on imaging) in a Phase I trial completed by Reata Pharmaceuticals, Inc. (NASDAQ: RETA) 14 years ago. CNS currently holds the worldwide exclusive licensing to the Berubicin drug and it recently obtained Investigational New Drug designation for it from the Food and Drug Administration.
In addition to Berubicin, the company’s current developmental pipeline includes a second promising drug candidate, WP1244. Licensed from The University of Texas MD Anderson Cancer Center in the first quarter of 2020, WP1244 is a DNA-binding agent that represents a novel class of potential therapeutics.
WP1244 is designed using anthracycline and distamycin-based scaffolds, creating small molecule agents binding extended sequences of DNA. In vivo testing demonstrated high uptake with WP1244 in the brain and subsequent antitumor activity in orthotopic models of the brain. The drug candidate is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. CNS entered into a Sponsored Research Agreement with MD Anderson Cancer Center in May 2020, related to WP1244.
CNS Pharmaceuticals, in partnership with company sublicensee WPD Pharmaceuticals, Inc. (CSE: WBIO) (FSE: 8SV1) currently has several clinical trials in different stages of preparation, including three glioblastoma multiforme (“GBM”) studies for Berubicin, scheduled to begin in Q1 2021. These include a randomized, controlled Phase II trial in the United States and another Phase II in Poland, conducted by WPD. Both these studies will be conducted with adult candidates. WPD will also begin the first-ever Phase I pediatric trial with Berubicin in Poland. Other studies in the pipeline for a future date include a potential Phase I trial for Berubicin with pancreatic and ovarian cancer and lymphoma patients as well as a potential Phase I trial for WP1244 for central nervous system tumors.
The primary focus for Berubicin has been patients with GBM, one of the most aggressive forms of brain cancer currently considered incurable. Each year, nearly 15,000 new GBM patients are being diagnosed in the United States. With the optimal therapy (surgical resection, chemotherapy, radiation), the median survival rate is only 15-23 months. Nearly 100% of GBM tumors recur after first-line therapy.
The Phase II trials for Berubicin in adult candidates are designed to be:
Adaptive – the trial is designed to allow for modifications based on accumulated data from trial subjects
Randomized – the trial randomizes which patients receive Berubicin versus the control group, eliminating the bias and increasing statistical significance
Controlled – a control arm receiving the standard of care to compare the effectiveness of Berubicin against this standard, increasing the statistical significance
Potentially Pivotal – the trials are designed to provide, pending positive results, the data necessary to support CNS’s request to the FDA for an expedited pathway to further development or approval of Berubicin
CNS believes that Berubicin has the potential to become a standard of care for GBM and other forms of brain cancer. The current first-line therapy includes temozolomide (“TMZ”). Nearly 40% of patients are genetically predisposed to respond to, becoming resistant to the treatment quickly. Berubicin could potentially be a second-line drug in these cases. The remaining 60% of patients may not be affected by TMZ, making Berubicin a potential first choice.
At the close of the presentation, Climaco said the company expects to see the first data for the Phase II trial in Poland reported during the third or fourth quarter of this year.
For more information, visit the company’s website at www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Wednesday, January 27th, 2021UncategorizedComments Off on $CNSP Discusses Product Pipeline, Clinical Trial Plans, at H.C. Wainwright Bioconnect 2021 Virtual Conference
Canopy Rivers (TSX: RIV) (OTC: CNPOF) today announced that it will be releasing its third quarter fiscal year 2021 financial results before markets open on February 10, 2021. Detailed information regarding the company’s financial statements for the three and nine months ended December 31, 2020 will be available on the company’s profile on www.SEDAR.com and on the company’s website at www.CanopyRivers.com/investors. The company will host a conference call and audio webcast following the release of its financial results at 9 AM ET on February 10. Canopy Rivers President and CEO Narbe Alexandrian, Chief Strategy Officer and General Counsel Matt Mundy and CFO Eddie Lucarelli will host the call. A live audio webcast will be available online (https://cnw.fm/c3UOH). To join the call, dial the North American toll-free number at 1-888-390-0546 and use the confirmation # 18291365. A replay of the call will be available through February 17 by dialing 1-888-390-0541 and entering the replay code 291365 #.
Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 17 companies across various segments of the cannabis value chain. The company believes that bringing together people, capital and ideas raises the potential of the entire cannabis industry. By leveraging industry insights, in-house expertise and thesis-driven approach to investing, Canopy Rivers aims to provide shareholders exposure to specialized and disruptive cannabis companies. Canopy Rivers’ mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with its portfolio, the company is helping build the cannabis industry of tomorrow, today. For more information, visit www.CanopyRivers.com.
NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://cnw.fm/CNPOF
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
XIAMEN, China , Jan. 27, 2021 — Blue Hat Interactive Entertainment Technology (“Blue Hat” or the “Company”) (NASDAQ: BHAT) , a leading producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China , today announced it received a letter from the Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement. The letter noted that as of January 25, 2021, Blue Hat evidenced a closing bid price of its ordinary shares in excess of the $1.00 minimum requirement for the past 10 consecutive business days. Accordingly, Blue Hat has regained compliance with Nasdaq Marketplace Rule 5550(a)(2), and Nasdaq considers the matter closed.
About Blue Hat
Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China , including interactive educational materials, mobile games, and toys with mobile game features. The Company’s interactive entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, please visit the Company’s investor relations website at http://ir.bluehatgroup.com . The Company routinely provides important information on its website.
Contacts :
Blue Hat Interactive Entertainment Technology
Phone: +86 (592) 228-0010
Email: ir@bluehatgroup.net
Investor Relations: The Equity Group Inc. In China Adam Prior , Senior Vice President Lucy Ma, Associate
(212) 836-9606 +86 10 5661 7012 aprior@equityny.com lma@equityny.com
Wednesday, January 27th, 2021UncategorizedComments Off on $BHAT Regains Compliance with Nasdaq Minimum Bid Price Requirement
After experiencing years of noisy cabins courtesy of internal combustion engine vehicles, most drivers who go green are often surprised by how quiet the cabins of electric vehicles (“EVs”) are. EVs have eliminated not just carbon emissions but sound pollution as well. Conventional vehicles are powered by a combustion engine, which can be quite loud, but electric vehicles rely on a much quieter electric motor for propulsion.
Unfortunately, without a loud combustion engine drowning everything out, ambient road noise is much more obvious inside the cabin. To eliminated this noise, EV makers have been using technology similar to what makes noise-canceling headphones so effective. Israel-based tech innovation company Silentium has created a special acoustic technology dubbed the Active Road Noise Cancellation (“ARNC”) software that can successfully keep ambient road noise out of the cabin.
After being selected by South Korean-based global automotive supplier Hyundai Mobis as its preferred noise-canceling technology supplier, Silentium is looking to roll out its personal in-car sound environments globally. Although ARNC technology shares some similarities with the technology in noise-canceling headphones, it is more advanced to deal with the much larger volumes of air in car cabins.
So how does it work?
Six accelerometers are strategically placed on the vehicle’s chassis to continually monitor unwanted noise from the road. Once the accelerometers detect noise, they dispatch a signal to a control unit onboard the vehicle. Equipped with Silentium’s noise-canceling software, the on-board control unit then emits an equal anti-noise signal using the speaker system of the vehicle. The waves from the ambient noise and the ANRC’s anti-noise signal hit the ears of the vehicle’s occupants simultaneously and neutralize each other, hence the silent cabin.
Silentium’s ANRC technology is proven to work across quite a wide spectrum of frequencies, from 20Hz up to 1kHz. The company’s partnership has allowed it to work with several automotive suppliers as well as some global original equipment manufacturers (“OEMs”). At the moment, three production models on the market are equipped with the noise-canceling technology.
Jaguar Land Rover was the first automaker to announce that it had integrated Silentium’s ARNC software in three of its upcoming models back in October 2020. This came after several years of development. The noise-canceling technology has been integrated into the Jaguar F-PACE, Jaguar XF and Range Rover Velar. Silentium and Hyundai are now working on a global vehicle production program for a still-unnamed brand.
Speaking of superior technologies, Net Element (NASDAQ: NETE) launched a blockchain-based system intended to avail safe platforms for payment processing. The company is also in the process of completing a merger with a California-based electric vehicle maker called Mullen Technologies Inc.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Before psychedelic drugs returned to mainstream media, heralded and backed by all this new research that shows the therapeutic benefits and potential they may possess, many had known these substances to be drugs used by hippies and party-goers.
As the public perception of these substances changes, many ask, what is the possibility of the use of psychedelic medical treatment in the United Kingdom?
Last year, the MHRA (Medicines and Healthcare products Regulatory Agency) authorized a clinical trial that would look into the potential of DMT as a treatment for various mental health conditions, such as depression. In addition to this, the UK also plans to launch its first medical psychedelic health center in Bristol this year.
The clinic’s objective will be to provide psychedelic drug treatments for a range of disorders including addiction, depression, anxiety and post-traumatic stress disorder. Because ketamine is used as an anesthetic and a legal medical product in the UK, ketamine-assisted psychedelic psychotherapy will also be available at the clinic, with a limit of 30 to 40 patients every month.
Conversely, psilocybin and MDMA are classified in the schedule 1 of the Misuse of Drugs Regulations, 2001. In other words, this means that these substances cannot be prescribed legally outside a clinical setting despite their use in clinical trials. Additionally, for one to supply, possess or produce these substances, a Home Office license is needed.
The Bristol clinic will also provide therapists with training in psychedelics, as well as conduct more research into MDMA and psilocybin, which is the psychedelic compound found in magic mushrooms. This research will be used to back the utilization of these psychedelic substances in psychotherapy in the future.
This is not the only facility that intends to conduct more research on these substances, as there are various clinical research projects being carried out across the globe that have the same end goal: to gather the evidence required to back a meaningful change in policy on the legality of psychedelics.
AWAKN Clinic’s chief medical officer, Dr. Ben Sessa, also conducted a study that showed significant promise in the use of MDMA as an alternative treatment for alcohol use disorder. His research was reported in a recent “Neuropharmacology” journal.
Despite psychedelics being illegal in many countries across the globe, a shift can be seen in the way that the public perceives these substances.
Many hope that this will rub off on UK health officials, who seem opposed to embracing the potential that psychedelics possess.
In nearby Canada, Cybin Inc. (NEO: CYBN) is taking full advantage of the resurgent interest in psychedelics and functional mushrooms. The company has so far raised more than $8.2 million during its initial funding round.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According to the announcement, POAI’s previously announced offering closed with 2,200,000 shares of common stock being sold, at a price of $1.00 per share. The gross proceeds for POAI was $2.2 million, with the company planning to use the funds for working capital purposes. Placement agent fees and other expenses related to the closing will be deducted from those proceeds. The company also announced that, in a concurrent private placement, it had issued to the same investors unregistered warrants to purchase up to 1,100,000 more shares of common stock; the exercise price for those will also be $1.00 per share. The cost for all shares was priced at-the-market under Nasdaq Rules. The newly announced registered direct offering comprises the issuance and sale of approximately 3,414,970 shares of POAI common stock. The offering is at a purchase price of $1.20 per share, also priced at-the-market under Nasdaq rules; the offering should result in gross proceeds of approximately $4.1 million for Predictive Oncology. All shares are part of POAI’s previously announced registered direct offering, filed with the Securities and Exchange Commission (“SEC”) in October 2019 with an effective date of Dec. 19, 2019.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA (“DNA/RNA”) and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Friday, January 22nd, 2021UncategorizedComments Off on $POAI Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering
Creatd (NASDAQ: CRTD), a proprietary technology platform for creators of all types, has unveiled two new creator challenges for its Vocal platform subscribers. The two challenges — Mystery of Bitcoin Challenge for all subscribers and both freemium and premium Vocal+ paid subscribers and Hometown Feature challenge for Vocal+ subscribers — include cash prizes for the winners. The Mystery of Bitcoin Challenge focuses on the origins of cryptocurrency and invites Vocal creators to submit a fictional story about the who, how and why of Bitcoin’s origin as well as the identity of its unknown inventor. The Hometown Feature Challenge provides an opportunity for Vocal+ members to show off their favorite hometown locales by submitting original film photos, digital images, phone pictures, Polaroids or videos that capture what makes their hometown special. Vocal hosts these Challenges to give back to its creator communities throughout the year. “Vocal is a creator-first platform and, while brand participation is a key component of a Challenge’s success, it is important that we additionally maintain a regular stream of Vocal-sponsored Challenges to advance the voice of creativity,” said Creatd Founder, president and head of product Justin Maury in the press release. “Part of how we do that is by offering an array of Challenges along multiple subscription tiers. Vocal+ Challenges represent a significantly higher reward for participation while other Challenges offer less cash incentive but are still a great introductory opportunity for our freemium tier members. I am proud to announce that, as of today, we have a record number of six active Challenges currently open for participation.”
Creatd empowers creators, brands and entrepreneurs through technology and partnership. Its flagship technology, Vocal, is a best-in-class creator platform. For more information about the company, please visit www.Creatd.com.
NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Despite the market starting low in the morning, by midday, many penny stocks were up on January 22nd. There are a lot of factors influencing the stock market today. With lower-priced stocks, volatility continues playing a big role. With so many different investing styles out there, this can be a major benefit to some but pose a big risk to others.
Right now, we are seeing heightened popularity across several industries. This includes tech, biotech, and energy penny stocks . With the pandemic still in full swing, we have to consider how these industries could be affected. For biotech penny stocks , the effect is quite obvious, but it differs depending on if the company is involved in vaccine treatments or not.
For other industries, we have to consider how the pandemic will impact things like revenue & continuing operations in both the short and long term. With this considered, here are four penny stocks that saw strong momentum on Friday. Will that continue into the end of January?
One of the bigger gainers of the day was MTC stock. By the afternoon on Friday, MTC stock had shot up by almost 28% to $2.43 per share. In the past month, shares are up by almost 50%, and since September, by around 200%. This rise reflects the company’s placement in the online tech services and solutions market.
MMTec provides internet-based tech products for Chinese financial firms. This includes its platforms known as ETN Counter Business System, PTN Private Mutual Fund Investment Management System, Personal Mobile Transaction Client System, and others. Based in Beijing, MMTec aims to be the leading digital solutions provider to the Chinese finance market.
While no news came out on Friday that sparked this gain, we can look at MMTec’s business model to try and find an explanation. A few months ago, the company announced an exciting report for its half-year 2020 financial results. In the report, the company stated that revenue increased by roughly 85%, with the cost of revenue decreasing by over 80%.
Additionally, the company managed to lower its operational losses by around 30% to $1.04 million for the six month period ending on June 30th. The company stated that it believes Chinese investors will continue to demand services for investing in U.S.-based assets. This could be especially true considering the election of Biden and the potential for U.S.-China tensions to ease.
AzurRX Biopharma Inc.
If you thought MTC’s daily gain was large, on Friday, shares of AZRX shot up by roughly 63% to over $2 per share. As a biotech company, AzurRX Biopharma works on several drugs for its pipeline, including treatment for certain symptoms of Covid-19. This seems to be one of the major reasons for the recent bullish interest in AZRX stock. In January, the company announced that it had signed a licensing agreement with First Wave Bio to use its proprietary formulation of niclosamide. The goal is to begin utilizing this treatment to fight Covid-19 related gastrointestinal issues. While the hype around covid-related biotech companies is high, there is some merit to this bullish interest.
What’s more, the company has other pipeline treatments gaining traction. On Friday, the company announced that it began dosing its first patients in the Phase IIb study of MS1819, a treatment for cystic fibrosis. The company states that it expects topline data from the study to be released within the first quarter of this year. AzurRX is a company with a lot of projects that are currently in the works. Because of this, it has seen a great deal of heightened popularity in the past few months. Will it be on your list of penny stocks to watch heading into February?
Oragenics Inc.
While OGEN stock only posted a 10% gain so far on January 22nd, this is still a relatively large jump in value. We’ve covered Oragenics Inc. several times in the past few months for its relation to Covid-19. The company is working heavily right now on its Terra CoV-2 Vaccine candidate. This could combat covid similarly to other existing vaccines. Also, the company is using this technology to find potential uses outside of Covid. In March of last year, Oragenics acquired a non-exclusive license from the NIG for its Terra CoV-2 spike protein.
Only a few weeks ago, the company announced that it had entered into a material transfer agreement. The agreement made with Adjuvance Technologies Inc. will utilize the adjuvant known as TQL1055 in Oragenic’s Terra CoV-2 vaccine.
Alan Joslyn, CEO of Oragenics, stated that “the execution of this material transfer agreement is an important step in the ongoing development of our Terra CoV-2 vaccine. Following our Type B Pre-IND meeting with the FDA, we were asked to conduct additional preclinical animal testing for inclusion in our IND filing. Because our vaccine uses an adjuvant, we anticipate a more intense immune response from our perfusion stabilized spike protein with a lower antigen dose.”
Synthetic Biologics Inc.
Another penny stock that we’ve covered several times in the past few months is SYN stock. Synthetic Biologics is a clinical-stage biotech company developing several novel therapeutics. Its focus is on the gastrointestinal illness market, working to meet otherwise unmet pharmaceutical needs. This includes its drug known as SYN-004 (ribaxamase), currently in trials to treat GI diseases. In an exciting announcement, Synthetic Biologics stated that the Washington University School of Medicine in St. Louis approved the Phase 1b/2a clinical protocol relating to ribaxamase. This is an exciting announcement as it allows SYN to move on to the next stages of the approval process.
Steven Shallcross, CEO of Synthetic Biologics, stated that “approval of the Phase 1b/2a clinical protocol by Washington University’s IRB is an important step in pursuing a potentially more cost-effective development strategy for SYN-004, targeting a highly specialized patient population. We expect to commence enrollment of patients in the first quarter of 2021 and look forward to providing further updates as we advance this exciting program.”
This was an exciting update for investors to consider. For biotech companies, announcements like these can show the market where a company is at in the various stages of approval. While the exact timeline moving forward remains to be seen, SYN could be one of the penny stocks to watch before the end of the month.
News Provided by PennyStocks.com via QuoteMedia
Friday, January 22nd, 2021UncategorizedComments Off on $AZRX Top Penny Stocks To Buy Right Now? 4 To Watch Before Next Week
Loop Insights (TSX.V: MTRX) (OTCQB: RACMF) announced that it will be providing its complete venue management for the upcoming Paiute Las Vegas Championship. Loop was selected by bdG Sports, a representation, event management, and public relations firm, which is organizing the event. The Paiute Las Vegas Championship is slated for April 12–18, 2021, and will take place at the Las Vega Paiute Golf Resort. The tournament is part of the Korn Ferry Tour, which is the primary pathway for golfers seeking to earn their PGA Tour card. Golfers competing in the tournament are those who have either not yet reached the PGA Tour, or who have done so but then failed to stay at that level. The event will feature 156 golfers competing for a $600,000 purse and, even more importantly, points toward earning their PGA tour card. The selection to use Loop’s venue management platform at the championship is an indication of the company’s ability to provide contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick-and-mortar space. “Loop Insights is proud to once again be selected as the venue management provider for bdG Sports and the Paiute Las Vegas Golf Championship,” said Loop Insights CEO Rob Anson in the press release. “The multiple successful deployments of our venue management platform at major sporting events over the last three months demonstrate our global leadership ability to secure any venue through our complete end-to-end venue management solution. The scope of the Paiute Las Vegas Championship will again demonstrate the strength and scalability of our platform. We look forward to working with bdG Sports once again to protect all participants and attendees.”
Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. RACMF’s ability to integrate seamlessly into existing infrastructure and customize campaigns according to each vertical creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality and retail industries in Canada, the United States, the UK, Latin America, Australia, Japan and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network and sold through the TELUS IoT Marketplace. For more information about the company, please visit www.LoopInsights.ai.
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at http://ibn.fm/RACMF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Friday, January 22nd, 2021UncategorizedComments Off on $RACMF Announces It Will Provide Venue Management Platform for Paiute Las Vegas Golf Championship
SRAX Inc. (NASDAQ: SRAX) to Host, Present at B.Riley Securities 2021 Vision Day via its Virtual Events Platform
SRAX’s Sequire will host upcoming B.Riley Securities 2021 Vision Day via its Sequire Virtual Events platform
In addition to hosting virtual event, SRAX will also be presenting as one of bank’s top picks for 2021
SRAX has previously hosted LD Micro Main Event on its platform, an event which featured over 250 presenting companies along with distinguished panelists, including Shaquille O’Neal and 2020 presidential candidate Brock Pierce
As virtual conferences have proliferated in wake of COVID19, SRAX has capitalized on the growing movement via its proprietary events platform
SRAX (NASDAQ: SRAX), a financial technology company focused on unlocking data and insights for publicly traded companies through Sequire, its proprietary investor intelligence platform, has announced that it will be hosting the B.Riley Securities 2021 Vision Day via its Sequire Virtual Events platform. SRAX will also be presenting at the event as one of B.Riley’s top picks for 2021 (https://ibn.fm/EucAs).
Sequire’s Virtual Events platform, which enables companies to virtually present to institutional and retail investors, is the most recent addition to Sequire’s broad suite of products and services. The events platform will complement Sequire’s preexisting functionalities, which include allowing its subscribers to track their shareholders’ selling and buying trends, search and monitor key investors, track outstanding warrants, receive the latest company specific news and media and even create and send out customized shareholder surveys designed to bring forth their stake-holders’ insights and opinions (https://ibn.fm/wQW79).
“We recognize that virtual events are here to stay, and for public companies, the platform offers everything issuers need to host their meetings with maximum exposure,” stated SRAX Founder and CEO Christopher Miglino.
B.Riley Securities, a leading full-service investment bank and subsidiary of B. Riley Financial, provides corporate finance, advisory, research, and sales and trading services to corporate, institutional and high net worth clients. Nationally recognized and ranked for its high quality small-cap equity research product, the investment bank also helps structure initial, secondary and follow-on offerings, carry out institutional private placements, provide merger and acquisition (M&A) advisory, and support corporate restructuring and recapitalizations.
This year’s 2021 Vision Day will bring together a carefully curated group of U.S. institutional investors and senior management derived from B.Riley’s analysts’ 2021 Vision picks. The conference will feature brief company presentations which will take place in conjunction with a series of fireside chats touching upon a variety of pertinent topics, with the latter being held in 25-minute sessions and hosted by B.Riley Securities analysts.
Sequire’s hosting of the B.Riley Securities 2021 Vision Day comes shortly after parent company SRAX announced the purchase of LD Micro, a leading data and event company serving the small and micro-cap space in late 2020 (https://ibn.fm/wuYTC). Following the acquisition, Sequire hosted the 13th Annual LD Micro Main Event on December 14-15,2020 via its Sequire Virtual Events SaaS platform. The conference, which featured over 250 presenting companies in addition to exclusive interviews with Shaquille O’Neal and 2020 presidential candidate Brock Pierce, marked Sequire’s initial foray into virtual events and has paved the way for the platform’s future collaborations within the conference space.
“With the launch of this virtual conference, we are one step closer to our mission of creating the most comprehensive platform for issuers,” said Miglino.
Digital conferences have rapidly proliferated following the advent of social distancing norms and working from home statutes. SRAX, through its Sequire platform, has sought to position itself to capitalize from this movement – with the award of the B.Riley Securities Vision Day conference a glowing testament to the rising popularity of its service offering.
For more information, visit the company’s website at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
MINNEAPOLIS, Jan. 21, 2021 — Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced registered direct offering of 2,200,000 shares of its common stock, at a purchase price of $1.00 per share, which was priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering were $2.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. In a concurrent private placement, the Company also issued to the same investors unregistered warrants to purchase up to an aggregate of 1,100,000 shares of common stock at an exercise price of $1.00 per share. The warrants are exercisable immediately upon issuance and have a term and five and one-half years.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
The Company intends to use the net proceeds from the offering for working capital purposes.
The shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) were offered by the Company in a registered direct offering pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-234073), including a base prospectus previously filed with the Securities and Exchange Commission (the “SEC”) on October 3, 2019, that became effective on December 19, 2019. A final prospectus supplement and base prospectus relating to the registered direct offering was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and the accompanying base prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at 646-975-6996 or e-mail at placements@hcwco.com .
The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and the underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.
Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, please visit www.predictive-oncology.com.
Forward-looking Statements
Certain of the matters discussed in this press release contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include: market and other conditions and the intended use of net proceeds from the registered direct offering, a variety of other risks and uncertainties including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
Thursday, January 21st, 2021UncategorizedComments Off on $POAI Announces Closing of $2.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Net Element (NASDAQ: NETE), a financial technology company in the process of becoming a pure-play electric vehicle (“EV”) manufacturer through a pending definitive agreement with privately held Mullen Technologies Inc., has announced the hiring of John Taylor as vice president of manufacturing for Mullen Automotive. Taylor comes from Tesla, where he oversaw more than 12 major vehicle launches, including Tesla’s highly successful Model S; Taylor also has impressive experience in plant start-ups. Taylor’s deep engineering experience is invaluable as, in his new role, he will oversee Mullen’s manufacturing facilities fortheMX-05and MX-07 SUVs. Taylor earned a degree from the Philpot School of Automotive Design in Detroit in 1987 before joining General Motors, where he served as launch manager, operations manager, and machine and equipment manager. He joined Tesla in 2010 as one of the company’s first 50 employees, leading the advanced manufacturing engineering group. “The entire Mullen Team is excited to have John on board with us,” said Mullen Technologies CEO and chairman David Michery in the press release. “His automotive manufacturing experience, especially in the EV space is unparalleled. He has the exact skill set needed to take the MX-05 and MX-07 from show car to mass production. John’s first effort is overseeing our initial phase 1 manufacturing facility, which covers over 1 million sq. ft., with body assembly, paint and general assembly.”
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, this morning announced that the company’s President and Chief Executive Officer, Rodney Varner, will provide a company overview at the MoneyShow Accredited Investors Virtual Expo taking place virtually January 26-28, 2021. GNPX’s presentation will shine a light on recent advancements concerning its upcoming clinical trials for the treatment of non-small cell lung cancer. The company will present at 12:25 PM EST on Thursday, January 28th. The presentation will be available for replay on the company’s website and www.MoneyShow.com.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA(TM) (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Thursday, January 21st, 2021UncategorizedComments Off on $GNPX Slated to Present Trailblazing Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
While the natural resource industry seems to have taken a little while to join the fourth industrial revolution, progress is being made steadily as automation is adopted and implemented. The benefits of automation include payload optimization achieved by computers in a way that could not be replicated by people.
Global mining equipment producer CR Mining is among many that are dedicated to developing more technology for the natural resource industry. The company’s head of product strategy, Kevin Greenwood, explained that the digitization of mining had various benefits. Among them those benefits are the following:
Improvement in efficiency and productivity based on a deeper understanding of the mining process, valuable data analytics and better sensors.
The removal of variability, especially around manned equipment and operators, with the growing adoption of automation.
Additionally, the development of sensing devices that report detailed and complex information has also led to more productivity and fewer accidents on site. Greenwood goes further to explain that CR Mining is in the lead with regard to digital transformation because the company is focused on not letting its clients down.
Another key technological innovation is a reporting platform developed with features that are vital for mines. The Orion Data Analytics platform has been designed to provide machine performance and real -ime productivity data to operators at the mining site. The platform then conveys this data to either a tablet or mobile device for mining-site personnel. In addition to this, the platform offers insight on items such as the following:
Operator performance
Dig unit duty
Truck payload performance
Dig unit productivity
It should be noted that users of the platform can also customize the database and its tools to provide an account of additional factors.
As the mining industry shifts its gears into Industry 4.0, the adoption and implementation of automation will improve many — and perhaps all — mining processes, which will benefit not only mines but also the environment.
Digital innovation in mines reduces the environmental impact that they have on the environment while simultaneously reducing the energy consumed on a site. The elimination of fatalities will also produce safe working environments for mine personnel, which may make it easier to venture into asteroid or deep marine mining.
Furthermore, the use of simulation-based planning in mines will allow mining companies to analyze project operational performance and processes in a virtual setting, which decreases the cost and time spent in prospecting, exploring and other mining operations.
Meanwhile, Colorado-based Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) is dominating the uranium mining segment of the industry. The firm’s production capacity and in-ground resources are greater than those possessed by any other uranium mining company on U.S. soil.
NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
NEW YORK , Jan. 21, 2021 — DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today the appointment of Chris Chan as Senior Vice President of Employer Sales. Mr. Chan will be responsible for leading growth initiatives in the self-insured employer market. Mr. Chan brings a unique perspective and strong understanding of the self-insured employer marketplace for digital health and DTx solutions.
Mr. Chan was most recently Chief Marketing Officer at SleepQuest; a sleep apnea focused technology and telehealth company. Prior to that role, Mr. Chan was a founding member, team leader, and innovation imaginer at Mercer LABS, where he worked with employers to evaluate digital health startups, care delivery improvement, condition management, workforce strategy, and benefit design. He also served as founder and creative director of the Health Imagination Innovation Team at Willis Towers Watson. In this role, Mr. Chan grew sales and created a global innovation network of consultants working on projects related to emerging trends, behavioral economics, gamification, big data, wearable devices, and incentive design.
“Chris brings an extensive network of senior-level relationships and a successful track record of innovation and sales leadership in digital therapeutics, and we are very pleased to welcome him to the team,” stated Rick Anderson , President and General Manager of North America . “In his previous roles, he has been involved in the proliferation of some of the largest digital health interventions in the employer and payer markets. Chris has extensive expertise in bringing next-generation digital health products like ours to the large employer market and will be an asset to increase market penetration. We believe that Chris, along with our recently announced addition of Claudia Kraut as VP of Broker and Consultant Partnerships, significantly strengthens our Employer Market team.”
“I am thrilled to be joining Dario at this juncture of its development, and have been impressed with their solutions for addressing the needs of individuals living with chronic conditions,” stated Mr. Chan. “Dario’s evidence-based open architecture provides a platform for working collaboratively and transparently across the healthcare system and I look forward to being part of the team bringing this solution to members, providers, employers and their advisors.”
In addition to Mr. Chan’s experience, he is also the founder of Purple Light Idea Factory, an advisor to several digital health companies focused on the fields of caregiving, addiction, mental health, sleep, network contracting, behavioral health, and payment integrity.
Mr. Chan’s appointment will support the continued growth and expansion of the business and benefit Dario’s next-generation, AI-powered, digital therapeutic approach that delivers adaptive, personalized experiences designed to drive behavior change through intuitive, clinically proven digital tools and coaching that help individuals measurably improve health outcomes.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software, and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The highly engaging, user-centric MyDario ™ mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com
This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it states its belief that the addition of Mr. Chan and Ms. Kraut significantly strengthens its Employer Market team. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Thursday, January 21st, 2021UncategorizedComments Off on $DRIO Announces Hiring of Leading Digital Health Innovator as Senior Vice President of Employer Sales
Last week, local legislators in Massachusetts unanimously confirmed their support for a resolution that would decriminalize various psychedelics. The Somerville City Council heard the testimony of two individuals who had benefitted personally from the use of psychedelics therapeutically before approving the measure in a 9-0 vote. This measure was also backed by the mayor.
In addition to this, some council members debated the possible medical value of psychedelic substances, especially in mental health issues, as well as the failures of the drug war.
In a written statement to legislators, the Heroic Hearts Project, Bay Staters for Natural Medicines and Decriminalize Nature declared that by decriminalizing entheogenic substances, the state could make harm-reduction strategies the norm as health-care providers and therapists adopted these plants for spiritual, psychological and physical relief.
The organizations also stated that Somerville had the chance to not only put public health above imprisoning individuals in cases of abuse of controlled substances and addiction but also allow loved ones, neighbors and friends to seek the spiritual and physical relief that they require.
Under the approved measure, the enforcement of laws against psychedelics such as ayahuasca and psilocybin mushrooms would be among the city’s lowest priorities. The measure also requested that the county prosecutor stop pursuing cases for individuals who had been charged with distribution or possession of entheogens.
The resolution states that no employee, officer, commission, board, agency or department in the City of Somerville, including employees of the Somerville Police Department, should utilize any resources or funds of the city to help in the enforcement of laws that impose criminal penalties for the possession and use of psychedelic plants by adults.
Apart from this, the measure also highlights that the city would not permit the commercial sales of these entheogenic substances nor would it allow driving under the influence of the said substances.
At the end of the meeting, city council president Matt McLaughlin stated that he loved living in a city where the agenda in question was not controversial and received undivided support.
Additionally, the vote of approval allows Somerville to join other cities across the country that have also ratified psychedelics decriminalization. The first jurisdiction to decriminalize psychedelic substances was Washington, DC, through last year’s November ballot. Other cities that have also decriminalized the possession of fungi and plant-based psychedelics include Ann Arbor, Michigan; and Santa Cruz and Oakland, both in California.
In neighboring Canada, Cybin Inc. (NEO: CYBN) is on course to benefit from the $25 billion legal supplements market through its range of products made from fungi.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
Creatd (NASDAQ: CRTD), a proprietary technology platform for creators of all types and the parent company of Vocal, has announced its largest Vocal challenge to date to celebrate the one-year anniversary of the platform’s Challenges feature. The Little Black Book Challenge, was launched in partnership with Moleskin, the well-known notebook brand, and features the largest-ever Challenge prizes: $20,000 cash prize for the first-place winner, $5,000 for the second-place winner, and $1,000 for the third-place winner, with a free year of Vocal+ to ten runners-up. Vocal is a proprietary technology platform for creators, and the Challenges provide opportunities for creators to participate in themed-story contests. The specially branded Little Black Book Challenge prompts creators to write a fictional story on Vocal about what they would do if they unexpectedly received $20,000; the stories must contain a reference to a little black book, a tie-in to the iconic Moleskine notebooks. “Challenges are unique in that they simultaneously incentivize creators to actively participate in the Vocal community, while also giving them the floor to speak out on important issues and raise awareness for the things they care about,” said Creatd COO Laurie Weisberg in the press release. “In this particular instance, I am extremely grateful and excited about our first partnership with Moleskine. Challenges are one of the key differentiating features that make Vocal a community that creators and brands feel proud to be a part of. Here are a few examples of Vocal creators explaining the benefit of Challenges, particularly during these challenging times.”
Creatd empowers creators, brands and entrepreneurs through technology and partnership. Its flagship technology, Vocal, is a best-in-class creator platform. For more information about the company, please visit www.Creatd.com.
NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Thursday, January 21st, 2021UncategorizedComments Off on $CRTD Announces Little Black Book Challenge, Largest-Ever Cash Prize to Mark One-Year Anniversary
A researcher from Tel Aviv University has developed a way to produce dairy products from yeast. Professor Tamir Tuller from the university’s Department of Biomedical Engineering is the researcher behind this innovative development. Tuller worked together with Dr. Eyal Iffergan, a food technology entrepreneur, to set up Imagindairy, a start-up company that plans to make cow’s milk using yeast.
This development comes at a time when researchers are working on finding substitutes for milk because dairy farming damages not only the environment but also human health.
Tuller explained that Imagindairy’s objective was to create milk that contained all the nutritional contents of cow’s milk along with a similar texture, aroma and taste. The only things excluded from the equation would be the damage caused to the environment during dairy farming and the suffering that cows go through during the dairy process.
These parameters will make Imagindairy’s cheese and milk products healthier than milk that is obtained from animals because the products will not contain somatic cells, lactose and cholesterol.
In his report, Tuller explained that the start-up also includes food experts and Strauss Company food engineers. For now, the researchers are working on leveraging the milk proteins from yeast to produce cheese using those proteins. Tuller explained that this was a long process of improvement, especially considering that the product is not similar to substitutes, such as nut milks (soy or almond milk, for example).
Tuller added that the company plans to manufacture dairy products through the introduction of yeast genomes, resulting in products similar to those derived from animals. Tuller and his lab have spent more than a decade exploring and specializing in the engineering and modeling of gene expression through the use of machine learning, computational modeling of molecular evolution and biophysical simulations. The models are then used to facilitate the manufacture of heterologous proteins more efficiently, which in turn makes them cheaper.
Tuller explained that the genome of each living creature is comprised of genes that contain an encoded formula for making amino acid chains which manufacture proteins. However, the genome also has information that ciphers gene expression. He explained that this was a complicated process involving protein creation.
Aside from researching how to generate milk from yeast, another biotech company, CNS Pharmaceuticals Inc. (NASDAQ: CNSP), has placed its focus on finding solutions to the worldwide challenge of brain tumors. The company already has a drug candidate (Berubicin) undergoing clinical trials, which is giving patients with brain tumors hope that a treatment could soon be available.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Shares of AzurRx BioPharma Inc. (NASDAQ:AZRX) traded at a new 52-week high today of $1.39. So far today approximately 3.2 million shares have been exchanged, as compared to an average 30-day volume of 2.6 million shares.
AzurRx BioPharma Inc. share prices have moved between a 52-week high of $1.39 and a 52-week low of $0.37 and are now trading 242% above that low price at $1.27 per share.
AzurRx BioPharma Inc. (NASDAQ:AZRX) defies analysts with a current price ($1.27) 44.9% above its average consensus price target of $0.70.
AzurRx BioPharma Inc is a development stage biopharmaceutical company. The company is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome-related conditions. Its lead product candidate is MS1819, a yeast-derived recombinant lipase for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP).
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Thursday, January 21st, 2021UncategorizedComments Off on $AZRX 52-Week High Recently Eclipsed
AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, has begun its Phase 2b OPTION 2 extension study of MS1819. AZRX announced that the first two patients have been dosed in the extension study of MS1819, which uses immediate release capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The OPTION 2 extension phase design, which was recently announced by AzurRx, is designed to evaluate patients aged 18 years and older who have already completed the OPTION 2 crossover trial; the OPTION 2 extension study utilizes higher doses than those used in the OPTION 1 trial. The company announced that the two patients who have been dosed will continue to be treated for the duration of the next two weeks. “As expected, the Data Monitoring Committee (‘DMC’) remains supportive of our program with no safety concerns regarding the design and protocol of the study,” said AzurRx BioPharma chief medical officer Dr. James Pennington in the release. “Due to enrollment in the initial crossover trial being ahead of schedule, we are given an opportunity to thoroughly explore optimal doses and capsule types that will help guide our future development plans for MS1819 in a Phase 3 program. In the meantime, we will continue our preparation for a successful FDA meeting later this year.”
AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF) Celebrates ‘Most Successful Year Ever’ by Building Data Connectivity Solutions with Blue Skies Ahead
Digital connectivity and tracing innovator Loop Insights is developing contactless, digital wallet-based disruptive services in an era defined by the COVID pandemic’s distancing protocols
During 2020, as many businesses floundered, Loop recorded its most successful year ever by forging a variety of partnerships for government and retail solutions, consumer access to healthcare information, and the rebirth of select in-person events
Loop provided venue tracing and informational services as the tech resource for two NCAA sports bubble events during the year and is helping the travel and film industry to similarly renew productivity with minimized concerns about viral infection
Loop’s solutions are also providing disparate governments with the ability to work together with shared information on COVID-19 medical and security protocols while maintaining their own local authority through control of their data repositories
The year 2020 was a make-or-break period for many businesses as they scrambled to continue their operations during the COVID-19 pandemic. Decisions had to be made about staffing levels, policies to protect the health of employees and customers, and how to best connect with customers and the product supply chain as a result of efforts to reduce the risk of transmitting a contagion responsible for killing or debilitating millions of people (https://ibn.fm/smlZw).
Internet of Things (“IoT”) data connectivity innovator Loop Insights (TSX.V: MTRX) (OTCQB: RACMF) is celebrating its “most successful year ever” after finding itself positioned with the right product and service at the right time to capitalize on the exponential growth of highly connected consumers online as a result of the pandemic.
“Throughout the year, my team and I have worked tirelessly to create products and solutions that would gain the trust of our partners … so that they could have the confidence necessary to bring this into their global customer opportunities,” Loop Insights CEO Rob Anson stated in a recap of the company’s progress (https://ibn.fm/Fvruj). “I am happy to report that we have accomplished this goal and as a result of these world-class partnerships, are now on the cusp of participating in global opportunities we never thought possible at the beginning of 2020.”
Loop has deployed its digital Wallet as part of the company’s venue management platform, which provides venue-based tracing, real-time customer engagement, and AI-driven insights. As demonstrated by Loop during its deployments at two NCAA venue bubbles, the company’s platform offers a number of real-world applications that can be applied to a number of industries, including live sports, entertainment, film, travel, and many others.
CEO Rob Anson also noted that a number of significant developments in 2020 will still have further implications for the company moving forward into 2021. Loop has existing partnerships with Amazon Web Services for networking with government leaders, two product partnerships with TELUS to promote its products, and an existing partnership with NTT DATA (a subsidiary of Nippon Telegraph and Telephone) that all offer significant potential for expansion. Additionally, the company’s partnership with Vend, has led to a number of retail opportunities through the company’s exposure to 25,000 stores in over 140 countries.
Loop’s contactless solutions are also being employed in its Digital Connect Health Platform, which was launched this month to streamline patient interaction with medical providers. Through a simple wallet pass, patients can easily check-in for appointments, receive updates on testing, and be notified in real-time about virus tracing and other critical health information all connected by a digital ID.
“The attempted implementation of wildly varying COVID-19 medical and security protocols, as well as, restriction policies by health officials and government leaders from around the world, has clearly demonstrated how divided government leaders have become by jurisdictional lines due to the lack of a single platform capable of providing uniformity and consistency in the application of policies,” Loop’s news release about the platform stated (https://ibn.fm/1OQSn). “Recognizing this breakdown, in conjunction with input from those same government leaders, Loop Insights developed the Digital Connect Health Platform to be capable of connecting Provincial and Federal systems while allowing Provinces to fully maintain their jurisdictional authority by managing their own internal data repositories.”
Loop’s ability to provide governments and the private sector with the means of connecting their current legacy and antiquated systems is “so revolutionary that it has attracted the attention of global technology companies and has positioned Loop for success within healthcare,” Anson stated.
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at https://ibn.fm/RACMF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Thursday, January 21st, 2021UncategorizedComments Off on $RACMF Celebrates ‘Most Successful Year Ever’ by Building Data Connectivity Solutions with Blue Skies Ahead
Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, has announced that it will be hosting a virtual roadshow next month. The event is scheduled for 11 a.m. ET on Wednesday, Feb. 3, 2021. Trxade Group CEO Suren Ajjarapu will host the presentation, which will include an overview of the company’s business model and an outline of growth initiatives. The webinar will also include a question-and-answer session. The entire presentation can be accessed via webcast link or dial-in numbers. Those interested in the webcast can register before the event, then sign in to view the presentation on the day of the event. Those interested in listening to the presentation can call 1-844-512-2921 within the United States or 1-412-317-6671 internationally. Those calling in should dial in at least 10 minutes before the presentation begins. In addition, the webcast will be available for replay through Feb. 17, 2021, by calling 1-844-512-2921 within the United States or 1-412-317-6671; enter replay pin number 13714981. The webcast will also be available for 90 days on the IR section of the Trxade Group website.
Headquartered in Tampa, Florida, Trxade Group is an integrated drug procurement, delivery and healthcare platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making healthcare services affordable and accessible. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; (1) the Trxade B2B trading platform with around 11,800 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; and (3) the Bonum Health platform offering affordable telehealth services. For more information about the company, please visit www.Trxade.com and www.BonumHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) has announced a partnership with C.A. Fortune E-Comm, the online arm of C.A. Fortune, to offer WTER’s A88 family of beverages across various e-commerce platforms. The partnership is effective Jan. 21, 2021, and platforms include Amazon.com, Walmart.com, Kroger.com, Thrive.com, Boxed.com and zulilly.com among others. WTER is a producer of premium bottled alkaline water, flavor-infused waters, and CBD-infused products sold under the brand names Alkaline88(r), A88 Infused(TM), and A88CBD(TM) respectively. In the announcement, WTER noted that the C.A. E-Comm team includes account representatives, inventory specialists, content specialists and data analysts. These experts will assist in efforts to grow the Alkaline88 brand on various leading retailers’ online platforms; the C.A. E-Comm team will also support WTER with day-to-day marketing and promotional planning, troubleshooting pricing issues, a deep-dive performance analysis, optimized content development and invoice management. “We are committed to growing our brands across all channels and excited to partner with C.A. E-Comm to capture the booming demand in online grocery sales,” said The Alkaline Water Company president and CEO Ricky Wright in the press release. “Digital sales for consumer goods have surged during the pandemic, with channels reporting triple-digit growth for this segment. This partnership further strengthens our relationship with C.A. Fortune, who has been a vital partner in our journey to becoming a national lifestyle brand. Our entire A88 beverage line will be available for our customers on various e-commerce platforms of major retailers. This is an incredible opportunity with a team that has helped brands enhance their online sales since 2004. We believe this opportune partnership can help us capture new share in the growing e-commerce segment.”
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, please visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
Consumers bracing for COVID’s impact into 2022 with what is being dubbed “homebody economy”
Pandemic has led to demand spikes, changes in consumer supply and buying patterns
WTER has seen significant market share growth; ideally positioned to continue to expand
A recent survey indicates that consumers in a post-pandemic environment are likely to be cautious in their buying habits, as many expect continued impact moving into 2020; survey respondents indicated an estimated 40% increase in intent to purchase online (https://cnw.fm/yrmni). (The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) has an aggressive growth strategy that includes a direct-to-consumer, e-commerce platform— www.A88CBD.com — along with a compelling digital-marketing campaign, which place the company in a strong position in the post-COVID environment.
“Consumers continue to shift to online shopping across categories, with many consumers planning to shift almost completely online after COVID-19,” reported a recent McKinsey and Company survey. “Americans are trying new digital habits and intensifying usage of digital behaviors such as grocery delivery and restaurant delivery.”
These consumers are looking for both convenience and value as they search out new brands. While many Americans are eager to spend more time with family and friends, they are not eager to return to grocery stores and restaurants. What is being dubbed the “homebody economy” is expected to stick post-COVID. Around 53% of Americans believe their routines will not return to normal until well into 2021 or even later.
Major shifts in consumers’ online spending focus on small businesses and e-commerce. This was seen in consumers’ online shopping patterns during Cyber Monday 2020 (with an increase in 15.1% from 2019), Small Business Saturday (with 30.2% growth) and Sunday (23.7% growth). Consumers are also focusing their purchases on groceries and health and wellness products (https://www.cnw.fm/oci3Q).
WTER looks to be well positioned to benefit from the new buying patterns. The top bulk-alkaline-water brand is committed to strengthening its presence in the e-commerce and online grocery shopping spaces as the demand for flavored waters, sustainable packaging and CBD are leading in health, wellness and lifestyle trends. The company has two online sites: one for CBD-infused products — www.A88CBD.com — and one for its flagship beverage products — www.TheAlkalineWaterCo.com.
“The pandemic has led to demand spikes and changing consumers supply and buying patterns, which we believe have finally begun to normalize,” WTER CEO Ricky Wright stated during the company’s November earnings call (https://cnw.fm/QQ3BZ). Wright also noted that the company had implemented aggressive promotional spending over the summer, resulting in increased market share.
“According to the total U.S. all-sales channels Nielsen’s report dated October 3, our flagship brand has been the fastest-growing, non-flavored, value-added water of the top 10 brands over the last 13-, 26- and 52-week periods,” he said. “Per Nielsen’s over the last 26 weeks, our brand has grown 17.7% compared to the category growth of a negative 0.3%. Over the previous 13 weeks, our retail sales have exceeded our quarterly average. And we’re robust — 23.2% more than double the category growth. In the last 26 weeks, we have also gained roughly 0.4% market share. This is equivalent to almost $8 million in annual retail sales. During the same period our top selling SKU has become one of the top 10 in the value-added water category in the entire country. We remain the only top 10 value-added water that has grown double digits in every four-week period since January.”
As one of the fastest growing alkaline water companies in the United States, WTER has continued to expand its brand. The company was able to enter the grocery and supermarket channel and provide products in more than 70,000 retail locations nationwide, including Walmart, Kroger, Albertsons, Safeway and Publix. Several single SKUs have also been introduced to these grocery stores. In addition, WTER is pursuing distribution to convenience stores, drugstores and specialty retail channels. Due to COVID, these stores have aligned their merchandise to include healthier, convenient items.
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. Additionally, in 2020, the company launched its A88CBD Infused line of ingestible and topical products, including its CBD water.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
Pressure BioSciences (OTCQB: PBIO), today announced a collaboration with SinuSys Corporation aimed at evauating the potential for PBI’s innovative Ultra Shear Technology(TM) (“UST”) platform to strengthen the effectiveness of SinuSys Corp’s lead product candidate Restora. Depending on the outcome of the collaboration, SinuSys plans to license PBI’s UST platform for use with Restora on its path to FDA approval in a phase IIb clinical study later this year. PBIO is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology services to the worldwide biotechnology, biotherapeutics and other industries. SinuSys Corporation is a medical device company focused on developing new therapies to improve the sinus health of patients. “Our patented UST platform is a unique breakthrough for nanoemulsification processing designed to resolve multiple substantive problems facing manufacturers of therapeutic drugs, nutraceuticals, and other products containing hydrophobic (water repelling) active ingredients that are at best poorly soluble in water,” said PBI chief science officer Dr. Alexander V. Lazarev in the press release. “Poor water solubility results in lower absorption rates and requires much higher loading of the active compounds into products to achieve targeted dosing and bioavailability of active ingredients for the patient. Unfortunately, poor water solubility also carries overdosing risks in conventional emulsions due to oil and water phases further separating and leading to non-uniform drug distribution. Scientific publications have demonstrated that hydrophobic active ingredients manufactured into high-quality nanoemulsions with droplet sizes of less than 100 nanometers can facilitate increased absorption and bioavailability while lowering doses and improving controlled release. This should result in better quality products and treatment experiences for the patient, with overall reduction in product costs.”
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Wednesday, January 20th, 2021UncategorizedComments Off on $PBIO Announces Collaboration to Evaluate Feasibility of Ultra Shear Technology Platform to Improve Effectiveness of SinuSys Lead Product Candidate
The combination of chemotherapy and particle-mediated heat treatment brings about synergistic effects in the elimination of cancer cells. This proposes that the technology may be a useful tool in the fight against cancer.
The nanoparticles are made from iron oxide, which make them magnetic. These particles can be stimulated to generate a mild heating effect by using an alternating magnetic field. This mild rise in heat warms nearby cells to nearly 42º Celsius. While cancer cells die when exposed to this heat, healthy cells in an individual’s body can withstand the rise in temperature. The method is minimally invasive as the magnetic field can be directed at the site of the tumor and applied outside the individual’s body.
As mentioned above, the particles can deliver chemotherapy drugs to a tumor in an individual’s body, which helps restrict the tumor’s exposure to healthy tissues in other parts of the body. The particles have a polymer coating, which prevents them from releasing their drug until they have been absorbed in the lysosomes found in the cancer cells. The lysosomes’ acidity causes the particles’ polymer coating to disintegrate, thus allowing it to release the drug and bringing about the elimination of cancer cells. It should be noted that the coating also releases the drug when there is a rise in heat.
Thus far, researchers have tested the nanoparticles with various types of cancer cells that have been grown in the lab. The researchers discovered that delivering chemotherapy drugs, in particular doxorubicin, a common chemotherapy drug, while applying heat simultaneously resulted in synergistic effectiveness.
Nguyen TK Thanh, a researcher participating in the study, explained that the study demonstrated the huge potential of combining heat treatment delivered through magnetic nanoparticles with chemotherapy treatments. She noted that while this combination of therapy had already been approved for the treatment for rapidly growing glioblastomas, the recent study findings propose that the treatment has the potential to be used more extensively as a therapy that fights against cancer.
She added that the therapy could also be used to decrease the side effects of chemotherapy on an individual by making sure it targeted cancer cells rather than healthy tissue in an individual’s body. However, more pre-clinical tests need to be conducted to explore this option.
Many other exciting developments are coming to light within the biomedical sector. For instance, TumorGenesis, a subsidiary of Predictive Oncology (NASDAQ: POAI), is working on a novel way to grow tumors within a lab without using mice or rats in the process. This technique will ease the task of studying the biomarkers of various cancers.
NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
